Laddar...
Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer
An article in a recent edition of Current Oncology explored the validation of progression-free survival (pfs) as an endpoint in clinical trials of antineoplastic agents for metastatic colorectal cancer, metastatic renal cell carcinoma, and ovarian cancer. The support for pfs as a surrogate endpoint...
Sparad:
| Huvudupphovsmän: | , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Multimed Inc.
2013
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3615866/ https://ncbi.nlm.nih.gov/pubmed/23559882 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.20.1226 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|